Biochemistry and beer and spirits and wine and vinegar and microbiology and enzymology and mutation or genetic engineering (C12)

C   Chemistry; metallurgy(318327)
C12            Biochemistry; beer; spirits; wine; vinegar; microbiology; enzymology; mutation or genetic engineering(33805)

Disposable system for sterile obtaining of lipids and nucleic acids particles // 2642640
FIELD: pharmacology.SUBSTANCE: group of inventions discloses a system for sterile obtaining of lipids and nucleic acids nanoparticles and method for sterile obtaining of lipids and nucleic acids nanoparticles.EFFECT: group of inventions allows to obtain uniform lipid and nucleic acid particles by simple steps, reproducible and under aseptic conditions, and can be used to deliver this class of therapeutic molecules to target cells.23 cl, 13 tbl, 7 ex, 1 dwg
ethod for prediction of cryoglobulinemic vasculitis development in patients with chronic hepatitis c // 2642626
FIELD: biotechnology.SUBSTANCE: method for prediction of cryoglobulinemic vasculitis development in patients with chronic hepatitis C (CHC) is proposed. A sample of the patient's genomic DNA is obtained, polymorphisms are detected in the ITGB3 1565 T/C and PAI-I-675 5G/4G genes, followed by analysis of their combination. The risk of cryoglobulinemic vasculitis development is determined by the formula.EFFECT: invention allows to isolate a high-risk group for cryoglobulinemic vasculitis development among patients with CHC and to recommend intensive antiviral therapy for these patients.4 dwg, 7 tbl, 6 ex
Set of oligonucleotide primers and probes and method for quantitative determination of fetal dna in blood of pregnant woman based on analysis of hypermethylated fetal dna sections // 2642622
FIELD: medicine.SUBSTANCE: method is proposed for obtaining of DNA primers and probes to determine the presence and the relative amount of fetal DNA in a plasma sample of a pregnant woman. A method and a set are proposed to determine the presence and concentration of fetal DNA in a plasma sample of a woman.EFFECT: effective detection of primer structures corresponding to the differentially methylated regions of the mother and fetus DNA.17 cl, 1 dwg, 4 tbl, 1 ex

ethod for chronic endometritis diagnostics at medium stage of secrection phase // 2642621
FIELD: medicine.SUBSTANCE: invention is intended for chronic endometritis (CE) diagnostics at the medium stage of the secretion phase. Pipelle biopsy of the endometrium using an atraumatic aspiration curette is performed to take a fragment of the uterine cavity mucous membrane at the medium stage of the secretion phase. By quantitative RT-PCR in real time, the mRNA level of the VEGFA gene is determined. At a level greater than 0.250, a conclusion is made about the presence of CE.EFFECT: effective diagnosis of chronic endometritis on the profile of genes mRNA expression in the endometrium during the implantation window in women with tubal peritoneal infertility.2 dwg, 3 ex

Expression method // 2642324
FIELD: biotechnology.SUBSTANCE: method for production of a protease protein by a bacterium of the Bacillus genus by the first expression construct introduction therein that encodes the target protease protein and the second expression construct that encodes an auxiliary protease with an amino acid sequence of SEQ ID NO: 1 different from the target protein and further expression of the said proteases in the said microorganism. A Bacillus genus microorganism is presented to obtain protease, which includes the first expression construct encoding the specified target protease and the second expression construct encoding an auxiliary protease different from the target protein with an amino acid sequence of SEQ ID NO: 1.EFFECT: group of inventions allows to increase the yield of target protease protein at microbiological fermentation.8 cl, 4 dwg, 2 ex
Recombinant producer of human omega-amidase nit2 based on escherichia coli // 2642323
FIELD: biotechnology.SUBSTANCE: invention relates to a recombinant strain of Escherichia coli BL21 (DE3; pQE-Nit2). This strain was obtained by transforming the Escherichia coli strain BL21 (DE3) by the plasmid construct pQE-Nit2, which is under the control of the T5 phage promoter and is designed to produce human ω-amidase (Nit2) when cultivated on nutrient media based on peptone, yeast extract and glucose. The peculiarity of the Nit2 gene in the pQE-Nit2 construct is optimized codon composition, as well as presence of an artificially introduced 6His- affinity tag immediately after the initiator codon ATG (Met), which allows one-step product purification by metal-affinity chromatography on Ni-NTA-agarose.EFFECT: invention allows to obtain human ω-amidase with an elevated yield.2 dwg, 1 tbl, 6 ex
Bacterial strains kit used for training on microbiology and plague laboratory diagnostics methods // 2642322
FIELD: biotechnology.SUBSTANCE: invention is a kit containing avirulent Yersinia pestis strains of pestis subspecies, orientalis biovar (KM 2011), pestis subspecies, antiqua biovar (KM 2008, KM 2012, KM 260 (12), km 130 (3)), pestis subspecies, medievalis biovar (KM 2010, 2014, 2024), caucasica subspecies (KM 2013), Yersinia pseudotuberculosis strains (KM 2004, 2005, 2006), Yersinia enterocolitica (KM 2007) and Pasteurella multocida strain (KM 2003), deposited in the State Collection of Pathogenic Bacteria "Microbe". A kit of strains can be used to train on microbiology and methods for laboratory diagnosis of plague.EFFECT: invention reduces the risk of students' infection.9 ex

Attenuated virus strain - biological preparation for cucumber plants protection against pathogenic strains of cucumber green mottle mosaic virus // 2642321
FIELD: biotechnology.SUBSTANCE: invention relates to an attenuated strain of the cucumber green mottle mosaic virus.EFFECT: invention effectively protects cucumber plants against pathogenic strains of the cucumber green mottle mosaic virus.2 tbl, 3 ex

Probiotic strains for treatment and/or prevention of diarrhea // 2642320
FIELD: biotechnology.SUBSTANCE: method for selection of a probiotic Bacillus strain, which includes assessment of the impact of the test strain on CFTR protein expression or NHE3 protein expression; Bacillus subtilis probiotic strain reducing CFTR protein expression and/or increasing NHE3 protein expression, deposited in the CNCM under accession number I-2745; cells obtained by cultivation of probiotic Bacillus strain, and a composition containing the effective number of cells for use in treatment and/or prevention of diarrhea.EFFECT: regulation of water absorption in the colon in the treatment and/or prevention of diarrhea.21 cl, 6 dwg, 2 ex

Genetically modified non-human animals and method for their application // 2642319
FIELD: biotechnology.SUBSTANCE: invention relates to genetic engineering, in particular genetically modified immunodeficient rodent expressing human M-CSF polypeptide, huma IL-3 polypeptide, human GM-CSF polypeptide, human SIRPA polypeptide and human TPO polypeptide. The rodent is modified so that its genome contains nucleic acids encoding human M-CSF, human IL-3, human GM-CSF, human SIRPA and human TPO, respectively. Each of the said nucleic acids is operably linked to a promoter. This invention also discloses a method for engraftment of a hematopoietic stem and progenitor cell (HSPC). This method involves HSPC administration to a genetically modified immunodeficient rodent according to the invention.EFFECT: invention allows to obtain genetically modified rodents demonstrating improved engraftment of solid tumours for use as models of the human immune system.19 cl, 17 dwg, 2 ex

Antigen-binding molecule, able to multiplely contact with plurality of antigenic molecules // 2642318
FIELD: biotechnology.SUBSTANCE: molecule containing a human antigen-binding domain and a FcRn-binding domain with antigen-binding activity different in two different conditions of calcium concentration and lower in conditions of low calcium concentrations compared to the conditions of high calcium concentration, where the low calcium concentration represents the concentration of ionized calcium of 0.1 to 30 mcm, and the high calcium concentration is ionized calcium concentration of 100 mcm to 10 mm, where the specified antibody contains at least four amino acids selected from the group consisting of amino acids at positions 30, 31, 32, 50 and 92, in accordance with the numbering along the Kabat light chain, with chelant activity against metal. Also, a pharmaceutical composition comprising the antibody is described. The invention can be used to accelerate the capture of the antigen by antigen-binding molecules into cells, increase the number of times of antigen binding by one molecule, accelerate the reduction of antigen concentration in plasma and increase the retention of an antigen-binding molecules in the plasma, as well as antigen-binding molecules.EFFECT: decreased antigen concentration in plasma.5 cl, 56 dwg, 28 tbl, 25 ex
ethod for production of vaccine against brucellosis of small cattle // 2642316
FIELD: biotechnology.SUBSTANCE: method for production of vaccine against the brucellosis of small cattle provides seeding and growing strain of Brucella melitensis Rev-1 on a nutritional medium, containing pancreatic digest of casein of a high decomposition degree, yeast extract, sodium chloride, glucose, glycerol, and agar-agar in the specified component ratio within 72 hours at 37°C. The grown vaccine culture is washed from the surface of the agar by a drying medium and brought to a concentration of 80-140 billion m.c. per 1 ml. It is checked for purity and dissociation, packed in ampoules and subjected to freeze-drying.EFFECT: increase in the yield of Brucella melitensis Rev-1 strain in the S-form.1 tbl, 1 ex

Recombinant plasmid pal2-t-wbmag dna, used for creation of dna-calibrators at therapy efficiency assessment for patients with acute myeloid leukemia // 2642315
FIELD: biotechnology.SUBSTANCE: invention relates to recombinant plasmid DNA. The recombinant plasmid pAL2-T-WBMAG DNA is developed, including fragments of WT1, BAALC, MN1, ABL1 and GUSB genes. The invention is used as calibrators in RT-PCR and real-time detection of genespecific products in order to compare the expression of these genes in patients with acute myeloid leukemia (AML). WT1, BAALC and MN1 genes act as tumour progression markers, and ABL1 and GUSB genes - as expression normalizers.EFFECT: invention allows to increase the assessment accuracy of the relative expression of these genes due to the DNA calibrators design that combine sequences of all markers, complex analysis of the WT1, BAALC and MN1 genes allows to evaluate therapy effectiveness in most cases of acute myeloid leukemia, including in patients without detected chromosomal aberrations.4 dwg

Set of primers and method for dickeya solani bacteria determination // 2642313
FIELD: biotechnology.SUBSTANCE: group of objects, including method for Dickeya solani bacteria determination by loop isothermal amplification (LAMP), and a set of primers for Dickeya solani bacteria determination by loop isothermal amplification (LAMP). In one of the versions of the invention in the reaction of target gene sequence plot amplification, a set of oligonucleotide primers is used, including: a FIP primer with a nucleotide sequence SEQ ID NO: 7, or its homologue, a BIP primer with a nucleotide sequence SEQ ID NO: 8, or its homologue, an F3 primer with a nucleotide sequence SEQ ID NO: 9, or its homologue, a B3 primer with a nucleotide sequence SEQ ID NO: 10, or its homologue; with these FIP, BIP, F3 and B3 primer homologues having homology not less than 95% compared to the corresponding nucleotide markers sequences SEQ ID NOs: 7, 8, 9 and 10, provided that such homologous primers can hybridize with the target infB gene coding the translation initiation factor IF-2.EFFECT: invention expands the arsenal of means for Dickeya solanibacteria determination.8 cl, 3 dwg, 2 ex
ethod for production of hydroxylated cyclopentapyrimidine compounds and their salts // 2642311
FIELD: biotechnology.SUBSTANCE: method for production of a formula III compound or a salt thereof, . The compound of formula or its salt is brought into contact with ketoreductase or alcohol dehydrogenase enzyme.EFFECT: invention allows stereoselective reduction of a compound of formula II or a salt thereof to a compound of formula III or a salt thereof that is suitable for further synthesis of ACT protein kinase activity inhibitors.15 cl, 3 dwg, 2 tbl, 6 ex
Application of phototrophic bacteria rhodobacter capsulatus pg lipopolisaccharide as factor affecting differentiation activity of 1alfa,25-dihydroxyvitamin d3 // 2642309
FIELD: biotechnology.SUBSTANCE: application of physiological lipopolysaccharide produced by the strain of the phototrophic bacterium Rhodobacter capsulatus VKM IBPM RAS B-2381D as a non-toxic factor enhancing the differentiating activity of 1α,25-dihydroxyvitamin D3 when monocytic-like cells are differentiated into monocytes, is proposed.EFFECT: invention can be used to further differentiate promonocytes and monocytes in clinical and experimental medicine and in development of drugs, in particular for oncology.2 dwg, 1 tbl

New fucosyltransferases and their application // 2642307
FIELD: biotechnology.SUBSTANCE: bacterial host cell is provided for production of fucosylated oligosaccharides containing an expression vector that encodes a polypeptide with alpha-1,3-fucosyltransferase activity and in which the sequence of the corresponding nucleic acid is operably linked to the control sequences. Appication of a polynucleotide encoding a polypeptide with alpha-1,3-fucosyltransferase activity to produce a fucosylated oligosaccharide is presented, which is performed by heterologous or homologous expression of a polynucleotide encoding an alpha-1,3-fucosyltransferase. A method for preparation of fucosylated oligosaccharides using the above bacterial host cell is provided.EFFECT: increased amount of fucosylated oligosaccharides, in particular 3-fucosyllactose, when using lactose as a substrate.10 cl, 9 dwg, 1 tbl, 1 ex

Lactobacillus strain having inhibitory activity against yeasts and mould fungi (versions), and its application // 2642306
FIELD: food industry.SUBSTANCE: strain of bacteria Lactobacillus paracasei DSM 25832, a strain of bacteria Lactobacillus plantarum DSM 25833, a strain of bacteria Lactobacillus plantarum DSM 25834, a strain of bacteria Lactobacillus plantarum DSM 25835, a strain of bacteria Lactobacillus plantarum DSM 25836, and a strain of bacteria Lactobacillus plantarum DSM 25837 are proposed. These strains have inhibitory activity against yeasts and mould fungi. The versions of a bacterial composition containing selected strains in combination with a bacterium of the Propionibacterium genus or another strain of the Lactobacillus genus are also proposed.EFFECT: obtaining a dairy product, applying in the yeast and mould fungi growth control method.17 cl, 8 dwg, 6 tbl, 3 ex

Cancer treatment using targeted antibodies in vivo // 2642305
FIELD: biotechnology.SUBSTANCE: antibody binding to claudine 6 (CLDN6) and inhibiting tumor growth in vivo is claimed. The antibody can be used as part of a pharmaceutical composition, in a method for treatment of tumor related to cells expressing CLDN6. The invention also relates to hybridomas producing antibodies to CLDN6 deposited under the accession numbers DSM ACC3059 (GT512muMAB 36A), DSM ACC3058 (GT512muMAB 27A), DSM ACC3057 (GT512muMAB 5F2D2).EFFECT: invention effectively inhibits the growth of CLDN6-positive germ cell tumors, improves survival and prolongs life of patients with tumors.17 cl, 18 dwg, 5 ex

Analysis of respiratory infection // 2642304
FIELD: medicine.SUBSTANCE: invention relates to a method for screening a biological sample for the presence of microorganism causing respiratory infection, selected from (i) respiratory syncytial virus (RSV A & B), (ii) rhinovirus, (iii) human metapneumovirus (hMPV), (iv) influenza B (Flu B Quad), (v) influenza A (Flu A CDC DC) and (vi) influenza A (H5 FRET) subtype H5, using real-time PCR and a test card having detection probes in individual wells.EFFECT: detection with a high level of sensitivity and specificity of target microorganisms.28 cl, 1 dwg, 2 tbl, 6 ex
Probiotic bacterial strain for obtaining nutrient composition improving sleep nature // 2642301
FIELD: biotechnology.SUBSTANCE: invention relates to application of a probiotic bacterial strain Lactobacillus reuteri DSM 17938 and/or Bifidobacterium longum ATCC BAA-999 in the manufacture of a nutritional composition for a subject. At that, the REM (REM+NREM) % ratio decreases by at least 8% compared to the subject that did not take such a nutritional composition, where REM is active sleep duration (minutes), and NREM is slow sleep duration (minutes).EFFECT: invention provides normalization of the sleep nature and improves the quality of sleep.12 cl, 2 dwg, 6 tbl, 4 ex

ethods of fermentation of carbohydrate-rich agricultural crops // 2642296
FIELD: agriculture.SUBSTANCE: method involves providing a carbohydrate-rich parenchyma tissue of a plant containing an apoplast at an agricultural crop temperature of 5 to 40°C. The said parenchyma tissue of the plant is combined with an aqueous solution containing yeast at a solution temperature of from 20 to 40°C. The said parenchymal plant tissue is influenced by the pressure of gaseous phase during preparation during the preparation time, or before the plant tissue is combined with the aqueous solution containing yeast, or after said combination. Wherein, the specified time of preparation varies from 1 minute up to 1 hour, but the pressure of gaseous phase in the preparation is less than the atmospheric pressure and ranges from 105 to 200% of the equilibrium vapour pressure at higher temperatures from the specified temperature of crop and the specified solution temperature. The said parenchymal plant tissue is influenced by the pressure of gaseous phase during infusions over time of infusions of from 1 minute up to 1 hour, where the specified yeast are infused into specified apoplast and where the specified pressure of gaseous phase at infusion is more than specified pressure of gaseous phase in the preparation. Free fluid is diverted, that was not drawn into the apoplast, then the pressure of the gaseous phase is supported at fermentation during fermentation time to obtain products of fermentation within the specified apoplast without re-entering the specified water solution containing yeast, in the specified parenchymal plant tissue. Wherein, the specified pressure of gaseous phase at a fermentation is greater than the specified pressure of gaseous phase at the preparation, specified fermentation time is from 6 hours up to 7 days, and the fermentation products are obtained by fermentation of carbohydrates, selected from a group consisting of simple sugars simple sugars obtained by hydrolysis of starch, and their combinations, and where carbon dioxide does not displace specified yeast from the specified apoplast during the fermentation.EFFECT: invention provides efficient fermentation of carbohydrate-rich crops.13 cl, 1 dwg, 5 tbl, 5 ex

Conditionally replicating adenovirus // 2642293
FIELD: medicine.SUBSTANCE: recombinant adenovirus is proposed for detecting cancer cells or diagnosing cancer containing a replicate cassette, a marker cassette, a gene that encodes the CD46 binding fibrillar protein. Specified replicate cassette is integrated into the part of E1 adenovirus genome and contains human telomerase reverse transcriptase promoter, E1a gene, sequence IRES and gene E1V in said order and sequence-target miR-142. The specified marker cassette is integrated into the part of adenovirus genome E3 and consists of reporter gene, promoter, able to regulate gene expression, and sequence-targets miR-142. Proposed recombinant adenovirus allows to detect cancer cells all over the body, including CAR-negative cells, wherein does not give false positive results in the detection of cancer cells to normal blood cells.EFFECT: diagnosis of cancer.4 cl, 8 dwg, 7 ex

ethod for determination of n-3 polyunsaturated fatty acid activity in fish oil sample // 2642292
FIELD: biotechnology.SUBSTANCE: in vitro method for determination of the presence of n-3 polyunsaturated fatty acid (PUFA) activity in a fish oil sample is provided. The first test system comprising the first mRNA sequence encoded by the first biomarker gene that has the first reporter protein coding region operably linked to the first marker promoter, is provided. The first test system is brought into contact with a standard substance or control substance. The second test system comprising the second mRNA sequence encoded by the second biomarker gene that has the second reporter protein coding region operably linked to the second marker promoter, is provided. The second test system is brought into contact with a fish oil sample. The first and the second marker genes are selected from the group consisting of nucleic acid sequences that encode a proapoptotic protein homologous to C/EBP (CHOP), ER protein, chaperone binding (BiP), transcription activation factor 4 (ATF-4), and protein I, connecting the X-box (Xbp-1). The transcription levels of the first and second mRNA sequences are determined. The fish oil sample is determined as having PUFA activity if the sample mediates positive regulation of marker gene transcription and the transcription level of the second mRNA sequence is higher than the transcription level of the first mRNA sequence.EFFECT: invention allows to examine food, nutraceuticals and medicines in terms of n-3 PUFA activity presence.13 cl, 1 dwg, 4 ex
Application of endogenic dnaase activity to reduce dna content // 2642290
FIELD: biotechnology.SUBSTANCE: method includes increase of the pH and/or temperature of the broth in which fungal host cells are cultured for at least 24 hours to a pH of 5.0-9.0 and a temperature of 30-70°C, respectively, incubating the broth at the said elevated pH and/or temperature for a period sufficient to detect a decrease in the host DNA content in the broth. At that, a decrease in the DNA content is not primarily due to the presence of exogenous DNAase in the broth. The method version further includes a step of liquid and solid phases separation to separate the broth from the host cells that are filamentous fungal cells. A method is also proposed for DNA content reduction in a protein preparation obtained from the said host cells. The method includes evaluation of the DNA level of the said host cells in a protein preparation obtained from fungal host cells, increase the pH and/or temperature of the protein preparation, determination of the reduction in the amount of DNA of these host cells in the protein preparation after incubation.EFFECT: invention effectively reduces DNA in the fermentive broth.24 cl, 4 dwg, 2 ex

Hpv chimeric particle // 2642287
FIELD: biotechnology.SUBSTANCE: chimeric virus-like particle (VLP) of human papilloma virus (HPV), and method for its production and extraction, methods for prevention or treatment of HPV infection or cervical cancer, and for induction of an immune response in the patient, including the administration of proposed HPV VLP, as well as the application of the proposed HPV VLP in these methods and in production of pharmaceuticals to implement these methods, are proposed. The proposed chimeric HPV VLPS has a diameter of about 30 nm and contains a chimeric polypeptide HPV 16 L1/L2, which consists of a polypeptide HPV 16 L1, in which the peptide HPV 16 L2 from the amino acid residue 414 is inserted. The peptide contains from 13 to 26 amino acids. The amino acids of the inserted HPV 16 L2 peptide replace the corresponding amino acids of the HPV 16 L1 polypeptide. A method is also provided for the production of said HPV VLP in a plant in which successful assembly of small chimeric HPV VLPs, having a diameter of 30 nm, takes place.EFFECT: proposed group of inventions can be used in medicine for the prevention or treatment of HPV infection or in antitumor therapy for cervical cancer.28 cl, 32 dwg, 11 tbl, 3 ex
ethod for production of target antibody with modulated galactosylation (versions) and method for modulation of target antibody galactosylation (versions) by culture medium optimisation // 2642285
FIELD: biotechnology.SUBSTANCE: methods for production of a target antibody with modulated galactosylation (versions), methods for modulation of the target antibody galactosylation (versions) by culture medium optimisation are provided. The methods provide increasing the osmolality of the solution for culturing animal cells and/or asparagine addition to the solution at a certain point in time of the cell culturing process.EFFECT: obtaining of the desired antibody population.19 cl, 3 dwg, 8 tbl, 3 ex

Cells derived from cardial tissue // 2642282
FIELD: biotechnology.SUBSTANCE: invention relates to a method for improving the contractility of the heart, increasing the capillary density, or reducing myocardial hypertrophy in a patient with a damaged myocardium, which can be used in medicine. This method includes an administration of a purified cell pool, derived from cardial tissue of a human, where these cells do not express telomerase, heavy chain of myosin, CD31, CD45 and CD16 and express GATA4, Nkx2.5, CD105, CD90, CD59 and CD54.EFFECT: invention allows you to effectively improve the contractility of the heart, increase capillary density or reduce myocardial hypertrophy in patients after acute myocardial infarction.16 cl, 39 dwg, 30 tbl, 20 ex

Thrombin-binding molecules of antibodies and their application // 2642276
FIELD: pharmacology.SUBSTANCE: isolated antibody molecule, specifically binding to the thrombin exosite area 1, and an antigen-binding fragment of said antibody, are provided. The use of the antibody molecule in the manufacture of medicaments is considered. A pharmaceutical composition is described as well as a method for treating a thrombin-mediated condition.EFFECT: use in the treatment of diseases associated with thrombin.25 cl, 22 dwg, 4 tbl
ethod of differentiating yersinia pestis strains on basic and nonbasic subtypes by pcr method in real time mode // 2642273
FIELD: biotechnology.SUBSTANCE: method of differentiating Yersinia pestis strains into basic and nonbasic subtypes by PCR method in the real-time mode is described. The method includes amplification of the tested DNA using engineered primers: ftKfor (5'-tcatcgttggtgtcagttgc-3'), ftsKrev (5'-tggcgatgatgacgttt-3') in the presence of allele-specific probes: ftsKProbaA (5'-Fam-aactggtacagaaAcaactgataca-RTQ1-3'), ftsKProbaG(5'-Hex-ggtacagaaGcaactgatacaaaa-BHQ2-3'), in the presence of fluorescent labels FAM and HEX and fluorescence quenchers RTQ1 and BHQ2.EFFECT: arsenal of ways of differentiating strains of Yersinia pestis is expanded.3 cl, 2 ex

edium for cell culture not containing oligopeptides // 2642269
FIELD: biotechnology.SUBSTANCE: protein-free medium for cultivation of CHO cells is described. The medium does not contain oligopeptides, contains amino acids, vitamins, organic and inorganic salts and sources of carbohydrates and is supplemented with at least 2 mg/l of 2HCl putrescine.EFFECT: inventions promote the growth of cells, their specific productivity and density.5 cl, 7 dwg, 11 ex
Application of cell line of 369 admel human skin melanoma // 2642265
FIELD: biotechnology.SUBSTANCE: specialized collection of vertebrata cell cultures of the Russian cell culture collection under the RCCC (P) registration number 727D. The cell line has stable cultural and morphological characteristics, is featured by the expression of differentiation tumor-associated antigens - MelanA, MITF, gp100, S100, tyrosinase, TRP-1; tumor-associated testis-specific antigens - NY-ESO-1 and MAGE, BAGE, GAGE, LAGE families.EFFECT: invention allows you to test the activity of various pharmaceutical products, create diagnostic sets and test systems to develop new pharmaceuticals and new therapeutic approaches, in particular, allows you to create a model system to determine the optimum doses of photosensitizer for photodynamic therapy, as well as to prepare antitumor vaccine based on activated dendritic cells.2 ex

Humanized antibodies, which recognize alpha-sinuclein // 2642262
FIELD: biotechnology.SUBSTANCE: antibody is described comprising a mature variable region of the heavy chain comprising three CDR according to Kabat from the sequence of SEQ ID NO: 44 and at least 90% identical to the sequence of SEQ ID NO: 44 and a light chain comprising three CDR according to Kabat from the sequence of SEQ ID NO: 45, and at least 90% identical to the sequence of SEQ ID NO: 45, where the antibody specifically binds to a human alpha-synuclein. A pharmaceutical composition comprising the described antibody is also described. A method of treating a patient having a disease with Levy bodies or having a risk of developing the disease or a method for detecting Levy bodies in a patient having a disease with Levy bodies or having a risk of developing the disease, comprising appointing to the patient an effective regimen for administering the described antibody, is provided.EFFECT: invention provides antibodies which bind to a human alpha-synuclein and can be used to treat and diagnose a disease with Levy bodies.80 cl, 6 dwg, 5 tbl, 2 ex

Polypeptide for blood sugar level reducing on basis of human glucagon-like peptide-1, recombinant producing strain e. coli and method of obtaining this polypeptide // 2642260
FIELD: biotechnology.SUBSTANCE: recombinant modified human glucagon-like peptide-1 (rmGLP-1), a method for its preparation, and strain E.coli RNCIM B-12555 are proposed. rmGLP-1 has the sequence of SEQ ID NO 1. rmGLP-1 is produced by culturing a recombinant strain E. coli RNCIM B-12555 to prepare the rmGLP-1 peptide precursor, then isolating the resulting precursor, its autocatalytic cleavage and purification of the target polypeptide. The mouse model shows that with subcutaneous or intramuscular administration, rmGLP-1 has indicators of sugar reduction activity and duration of action similar to that of the commercial preparation "Lysxemia" obtained using chemical synthesis and, for a minimum of 3 hours after administration, is able to effectively reduce the level of glucose in blood almost twice as compared with the control.EFFECT: abovementioned strain allows biosynthesis of the precursor rmGLP-1 at 40 percent of the total protein of the cells, which corresponds to the biosynthesis of rmGLP-1 at 13 percent of the total cell protein.3 cl, 3 dwg, 7 ex

Recombinant chimerical ntbi polypeptide-immunogen with ability to induce neutralizing antibodies to type 1 human immunodeficiency virus and intended for use as component of vaccine against hiv-1 // 2642258
FIELD: medicine.SUBSTANCE: recombinant chimerical polypeptide-immunogen is proposed, including conservative T- and B-cell epitopes of HIV-1 and consecutive peptide fragments of p24, gp41, gp120 proteins, recognizable by wide-neutralizing 10e8, 2F5, VRC01 antibodies.EFFECT: improved HIV-specific immune response due to the inclusion of unique linear conformational epitopes imitators, recognizable by wide-neutralizing antibodies into the polypeptide-immunogen nTBI.6 dwg, 5 ex
ethod for inactivation of cattle campilobacteriosis pathogen // 2642249
FIELD: biotechnology.SUBSTANCE: method involves accumulation of Campylobacter fetus subspecies fetus cattle campilobacteriosis pathogen colonies by culturing on a nutrient medium, flushing of the Campylobacter fetus subspecies fetus campilobacteriosis pathogen colonies with 0.9% NaCl solution, inactivation of the accumulated biomass of the Campylobacter fetus subspecies fetus campilobacteriosis pathogen by an inactivator and differs by teotropine application as an inactivator, with the following ratio of components, wt %: suspension of campylobacter cells of fetus subspecies fetus serogroup in a culture medium at a concentration of 2×1010 CFU*/cm3 (culture of the Campylobacter fenus subspecies fetus cattle campilobacteriosis pathogen) - 0.5%; 0.9% NaCl solution - 99.2%; teotropin - 0.3%.EFFECT: increased activity of the compound.1 tbl
Electrochemical method and system for obtaining glucose // 2641646
FIELD: chemistry.SUBSTANCE: method includes the reaction of water and dissolved gaseous carbon dioxide in the presence of a source of electromagnetic energy and melanin restrained on the substrate, so that glucose is obtained. The proposed system for the implementation of the method involves a reaction cell and a source of the electromagnetic energy, wherein the cell contains melanin on the substrate that restrains it.EFFECT: new effective method for obtaining glucose and a system for its implementation.13 cl, 2 ex, 1 tbl
ethod for determination of indications for antiherpetic therapy in case of hhv-6 infection in children with acute respiratory diseases // 2641609
FIELD: medicine.SUBSTANCE: method for determination of indications for antiherpetic therapy in case of HHV-6 infection in children with acute respiratory diseases is proposed. The PCR method with hybridization-fluorescent detection in "real time" mode is used to determine the number of HHV-6 DNA copies. For more than 100 copies/105 cells in the blood, indications for antiherpetic therapy are determined.EFFECT: possibility of infectious process correction, excluding the unreasonable use of antiherpetic drugs and preventing recurrence.1 dwg, 1 tbl, 3 ex
ethod for determination of genetic predisposition to atherosclerosis, ischemic heart disease and myocardial infarction // 2641568
FIELD: medicine.SUBSTANCE: DNA is extracted from the patient's blood, mitochondrial DNA (mtDNA) is genotyped, the degree of mtDNA heteroplasmia is determined by the m.652delG mutation. With a value above 22.5%, high genetic risk is judged.EFFECT: increased effectiveness and accuracy of determination of predisposition to atherosclerosis, coronary artery disease and myocardial infarction.4 ex

Flavoured milk composition // 2641264
FIELD: food industry.SUBSTANCE: method to produce the flavoured milk composition, comprising the strain of Lactococcus lactis subspecies lactis biovar diacetylactis DL2126, VTT E-123249 as the diacetyl producing strain and diacetyl in the amount of at least 50 mg/kg in the milky medium, is carried out as follows. Provide the Lactococcus lactis strain subspecies lactis biovar diacetylactis DL2126, VTT E-123249 and the fermentation medium, containing lactose, citrate, yeast extract and/or casein hydrolysate, and mix the specified strain with the medium. Cultivate the mixture for 10 up to 28 hours under the conditions optimized for pH, aeration, mixing and temperature to provide the specified composition of flavoured milk. The flavoured milk composition application, while manufacturing of a milk product. The milk product contains the flavoured milk composition. The Lactococcus lactis subspecies lactis biovar diacetylactis DL2126, VTT E-123249 strain is used for the milk product manufacture. The Lactococcus lactis subspecies lactis biovar diacetylactis DL2126, VTT E-123249 strain is used, while the milk product manufacture. The milk product contains the Lactococcus lactis subspecies lactis biovar diacetylactis DL2126, VTT E-123249 strain. The butter manufacturing method from the raw milk is carried out as follows. Separate the raw milk into the cream, containing about 40% of fat, and the skim milk. Pasteurize the cream, beat them to separate the butter beans and buttermilk. Process the butter grains, add the flavoured milk composition to the grains, normalize the mixture and prepare the butter.EFFECT: manufacture of products with increased ability to produce diacetyl.24 cl, 5 dwg, 1 tbl, 6 ex

ethod and device for production of acrylamide // 2641262
FIELD: chemistry.SUBSTANCE: method for the production of acrylamide from acrylonitrile and a device for carrying out the above method are provided. The device contains two or more connected in series A and B reactors, pipelines for supplying acrylonitrile, water and a catalyst in the upper stream of the reactor, a pipeline for releasing a part of the reaction liquid from the bottom of the reactor thread, a detection unit to determine the level of the reaction liquid in A reactor, and a control unit to regulate the volume of the reaction liquid. Moreover, the reactor A includes a circulating pipeline and a connecting hole with the reactor B located below the surfaces of the reaction liquids. The method includes regulating the volume of the reaction fluid in the reactor B through the control level of the reaction liquid in the reactor A, where the level of the reaction liquid in the reactor A is controlled by adjusting the volume of the reaction fluid that must be released and/or returned to the reactor A by circulation.EFFECT: invention provides a duration of incubation of the reaction liquid in the reactor suitable for the production speed, reducing the amount of the catalyst used.8 cl, 1 dwg, 1 tbl, 4 ex
Probiotic strain lactobacillus gasseri and its composition with lactoferrin for prevention of diarrhea, nerrocessing enterherolite and sepisis caused by escherichia coli strains in prematurely born children // 2641258
FIELD: biotechnology.SUBSTANCE: Lactobacillus gasseri strain of BK-2918D VKM having antagonistic activity against Escherichia coli strains and a composition containing the strain of Lactobacillus gasseri ECM B-2918D and lactoferrin have been claimed. Probiotic strain lactobacillus gasseri and its composition with lactoferrin for prevention of diarrhea, nerrocessing enterherolite and sepsis caused by escherichia coli strains in prematurely born children.EFFECT: expansion of the assortment of probiotic drugs and nutrient mixtures that provide the formation of normal microflora of the gastrointestinal tract in prematurely born children.2 cl, 3 dwg, 3 tbl, 7 ex

Heterodimerizated polypeptide // 2641256
FIELD: biotechnology.SUBSTANCE: polypeptide with cytotoxic activity, comprising an Fc region of IgG, which consists of a heterodimer containing the first polypeptide and the second polypeptide, in the amino acid sequences of which a series of mutations takes place. A pharmaceutical composition for treatment of a human disease associated with antigens with which the said polypeptide specifically interacts, comprising the said polypeptide and a medically acceptable carrier, is provided.EFFECT: group of inventions allows to optimize the effector function of the polypeptide by changing the function of the Fc region compared to the function of the Fc region of the polypeptide, which consists of a homodimer containing only the first or only the second polypeptide.7 cl, 54 dwg, 80 tbl, 29 ex

ethod of differential and confirming molecular-genetic diagnosis of congenital aniridia and wagr-syndrome // 2641254
FIELD: biotechnology.SUBSTANCE: method of differential and confirming the molecular genetic diagnosis of congenital aniridia and WAGR syndrome is described. The method provides that in a patient having clinical signs of aniridia, a sample of biological material is taken for the DNA diagnosis. Initially, large deletions with a size of at least one thousand base pairs of 11p13 region by the MLPA method are searched for. Based on the results of this search, further activities selected from the next set of diagnostic tools are produced. If a large deletion of the Hp 13 region, the locus of the WT1 and PAX6 genes, is detected and the deletions on the patient's genetic material are confirmed by fluorescent in situ hybridization (FISH) with a probe specific for the WT1 gene, the patient is exposed to a presumptive diagnosis of WAGR syndrome. In case of detection of large deletions of the 11p13 region that do not capture the locus of the WT1 gene and the locus of the PAX6 gene or its distant regulatory regions, and confirm deletions on the genetic material of the patient by the method of analysis of loss of heterozygosity by microsatellite markers, the patient is diagnosed with a congenital aniridia. In the absence of major deletions of the 11p13 region, sequencing of exons and flanking regions of the intron of the PAX6 gene is performed to find small intragenic mutations of this gene. Exons are sequenced from at least one of the groups: exon group 5, 6, 7, 8, 9 and/or exon group 1, 2, 3, 4, 10, 11, 12, 13. If a small intragenic mutation is detected as a result of sequencing, the pathogenicity of the detected genetic lesions in the PAX6 gene is checked in accordance with the ACMG (American College of Molecular Genetics) criteria. With evidence of the pathogenicity of the mutation, the patient is confirmed with a clinical diagnosis of congenital aniridia. Preferably, the genetic status of this change in the parents is determined to confirm the pathogenicity and clinical significance of the deletions or other mutations identified.EFFECT: invention provides an effective confirmatory protocol and differential diagnosis of congenital aniridia and WAGR syndrome, taking into account the pronounced clinical polymorphism and molecular heterogeneity.7 cl, 1 dwg
ethod for leprosy mycobacteria dna identification by polymerase chain reaction // 2641060
FIELD: medicine.SUBSTANCE: DNA is extracted from the scrapes from the nasal cavity mucosa in 5% solution of serum bovine albumin. Real time PCR is performed using external and internal primers.EFFECT: improved efficiency of leprosy causative agent identification.1 tbl, 2 ex
ethod for prediction of risk of multiple organ failure syndrome development in patients after heart bypass // 2641033
FIELD: medicine.SUBSTANCE: method for prediction of the risk of multiple organ failure syndrome in patients after heart bypass surgery is proposed. Clinical and anamnestic indicators are analyzed and molecular genetic testing is performed with determination of polymorphisms of TLR6 and TREM-1 genes. A rating score is assigned to each prognostic criterion. The minimum risk is predicted with a score of 0 to 2.5. The average risk - with a score of 3.0 to 4.0 points. The high risk - 4.5 to 5.5 points.EFFECT: effective prediction of the risk of multiple organ failure syndrome after heart bypass by determining polymorphisms of candidate genes and calculation of the total risk by an assessment scale based on point equivalent.7 tbl, 3 ex
ethod for detection of tumour growth pdcd4 suppressor suppression inhibitors in tumour cells and plucpdcd4 genetic construct for its implementation // 2640909
FIELD: medicine.SUBSTANCE: method for detection of inhibitors of suppression of Pdcd4 tumour growth suppressor in tumour cells and pLucPdcd4 genetic construct, which is a plasmid encoding a reporter protein that is a firefly luciferase chimera with a human Pdcd4 protein, is proposed.EFFECT: group of inventions allows to identify substances with known and presumed ability to inhibit Pdcd4 suppression in tumour cells as inhibitors of suppression of Pdcd4 tumour growth suppressor.4 cl, 4 dwg, 6 ex

Chiral diacylhydrazine ligands for modulation of exogenous genes expression by ecdysone-receptor complex // 2640807
FIELD: biotechnology.SUBSTANCE: invention relates to a method for preparation of an enantiomerically enriched compound with Formula III , wherein A is (C1-C6)alkyl-O-, phenyl- C1-C6)alkyl-O-; aryl selected from phenyl, naphthyl, benzo 1,3]dioxole, 2,3-benzo[1,4]dioxin which is optionally substituted by 1 to 3 substituents, where the substituents are selected from (C1-C6) alkyl, (C3-C7) cycloalkyl, (C1-C6)alkyl-O-, hydroxy, amino and halo; or heteroaryl having four or five carbon atoms and one heteroatom selected from oxygen, nitrogen and sulfur, which is optionally substituted by 1 to 3 substituents, where the substituents are selected from (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl-O-, hydroxy, amino and halo; B is phenyl optionally substituted by 1 to 3 substituents, where the substituents are selected from (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl-O-, hydroxy, amino and halo; and R1 and R2 independently represent (C1-C6)alkyl, phenyl-(C1-C6)alkyl-, hydroxy-(C1-C6)alkyl, (C3-C7)cycloalkyl, (C2-C6)alkenyl or (C2-C6)alkynyl; provided that R1 differs from R2; where the absolute configuration of the asymmetric carbon atom carrying R1 and R2, is an R-configuration; including (a) reaction of Formula XI acylhydrazine with Formula XII ketone to form a compound of Formula XIII , where R1 differs from R2, (b) reduction of the Formula XIII compound in the presence of a chiral catalyst to form a Formula R-XIV compound and (c) reaction of the Formula R-XIV compound with the Formula B-CO-LG compound, wherein LG is a leaving group, forming a compound with Formula III.EFFECT: chiral diacylhydrazine ligands for genome modulation.6 cl, 25 dwg, 11 tbl
Culture environment for mesenchymal stem cells of human // 2640556
FIELD: biotechnology.SUBSTANCE: invention represents cultural medium for human mesenchymal cells, including basal medium for mesenchymal stem cell, outer layer of white cells lysate/human platelets (buffy coat) from 5 to 20% (vol/vol); insulin from 2 from 20 mg/l; sodium selenite in quantities ranging from 0.005 to 1.730 mg/l; ethanolamine in quantities ranging from 1 to 8 mg/l and basic fibroblast growth factor (bFGF) in quantity from 5 to 25 ng/ml. Mentioned medium is supplemented with fetal bovine serum (FBS) from 10% to 20% (vol/vol) or additive cell culture derived from human plasma (CCS) from 10 to 40% (vol/vol).EFFECT: invention allows you to cultivate human mesenchymal cells lines, including those which do not grow up in a culture media, that typically use for the cells of this type.7 cl, 2 tbl, 2 ex

A n2269/vniizzh/2015 strain of type a aphtae epizooticae foot-and-mouth disease virus for control of antigenic and immunogenic activity and for manufacture of biopreparations for diagnosis and specific prevention of type a foot-and-mouth disease // 2640261
FIELD: biotechnology.SUBSTANCE: characterized strain is isolated from the sick cattle and obtained by successive passages on sensitive hetero- and homologous cell cultures and deposited in the collection of the FGBU "VNIIZZH" under the registration number strain VIA A2269/VNIIZZH/2015 (production), (control cattle), (control swine). The presented strain is reproduced in transplantable cultures of kidney cells of the Siberian mountain ibex (PSGK-30), IB-RS-2, VNK-21. During 17-24 hours of incubation, the virus yield in these cell cultures reaches the values of 6.75-7.75 lg TCD50/cm3. The presented virus strain can be used for control of the antigenic and immunogenic activity and for manufacture of biopreparations for diagnosis and specific prevention of type A foot and mouth disease.EFFECT: with high multiplicity of infection, causes CPD after 17-24 hours, maintaining the original characteristics when passaging in cell cultures for 5 passages.5 cl, 1 dwg, 7 tbl, 7 ex
 
2551395.
Up!